Rigor Reviewed

Rigor-Reviewed Manuscript

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.

Name: Αlpha¹ Rigor Record — Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
Item: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
Rating: 59
Author: Αlpha¹

Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, Liu Y, Sun J, Nie J, Lei R, Yao Y, Zhang A, Wang S, Ma X, Ouyang Z, Yang H, Wu SY, Cao SW, Wang K, Jiang A, Ouyang Q, Pang D, Wei L, Zha X, Shen Y, Qu X, Wu F, Zhu X, Wang Z, Fan L, Shao ZM

Paper source

Read full text (PMC)PDF

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 8 high issues for “Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized, double-blind, phase 3 trial with a clear scientific premise, rigorous design, and appropriate statistical reporting. The main weaknesses are missing explicit ethics approval and informed consent statements, an incomplete data sharing statement, and several minor reporting gaps (e.g., randomization method, sample size calculation, statistical software).

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence was present. The statistics verification component recomputed 1 reported test consistently, but this does not confirm the correctness of all statistics. The citation check found no retracted or non-existent references.

2 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites that camrelizumab has shown antitumor activity in advanced triple-negative breast cancer and that PD-1/PD-L1 blockade may improve efficacy of classic neoadjuvant chemotherapy. The objective directly follows from this premise. Limitations of prior research are not explicitly discussed, but the premise is well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific premise by citing prior research on PD-1/PD-L1 blockade in triple-negative breast cancer and the rationale for adding camrelizumab to neoadjuvant chemotherapy.

Evidence

direct quote[Introduction]

“Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti–PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.”

direct quote[Objective]

“To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer.”

absence[Introduction]

Limitations of prior research are not explicitly addressed.

PASSReviewer 2· 90% conf

The study clearly establishes its scientific premise by citing prior research on PD-1/PD-L1 blockade in TNBC and the rationale for adding camrelizumab to neoadjuvant chemotherapy.

Evidence

direct quote[Introduction]

“Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy.”

direct quote[Introduction]

“Camrelizumab, an anti–PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.”

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Randomization method is not detailed (e.g., block or stratification), but the trial is described as randomized and double-blind. A sample size calculation is implied by the phase 3 design, though not explicitly stated. Inclusion/exclusion criteria are not detailed in the abstract but are standard for a phase 3 trial. Blinding is stated as double-blind. Outlier handling is not applicable for a clinical trial with ITT analysis. Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingN/A

randomization unitADEQUATE

inclusion exclusionINADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, phase 3, with a pre-specified primary endpoint and sample size calculation.

Evidence

direct quote[Design, Setting, and Participants]

“Patients were randomized in a 1:1 ratio to receive either camrelizumab 200 mg (n = 222) or placebo (n = 219) combined with chemotherapy every 2 weeks.”

direct quote[Design, Setting, and Participants]

“This randomized, double-blind, phase 3 trial enrolled patients from 40 hospitals in China between November 25, 2020, and May 12, 2023 (data cutoff: September 30, 2023).”

absence[Methods]

Sample size calculation not explicitly reported.

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, double-blind, phase 3, with a pre-specified primary endpoint and sample size calculation.

Evidence

direct quote[Abstract, Design, Setting, and Participants]

“This randomized, double-blind, phase 3 trial enrolled patients from 40 hospitals in China”

absence[Methods]

Randomization method (e.g., block, stratification) is not described.

absence[Methods]

Sample size calculation is not reported.

Sex is reported as all females, and age is reported as median 48 years. Since the study is in breast cancer, which predominantly affects females, the single-sex enrollment is justified by the disease context. Demographics beyond age and sex are not reported in the abstract, but the study is a clinical trial where detailed demographics are typically in the full protocol.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study reports sex (all female) and age (median 48 years), which are the key biological variables for this patient population.

Evidence

direct quote[Results]

“Among 441 females randomized (median age, 48 years)”

direct quote[Results]

“median age, 48 years”

absence[Abstract]

Detailed demographics (race/ethnicity, comorbidities) not reported in abstract.

PASSReviewer 2· 90% conf

The study reports sex (all female) and age, but lacks detailed demographics such as race/ethnicity and comorbidities.

Evidence

direct quote[Results]

“Among 441 females randomized (median age, 48 years)”

direct quote[Results]

“median age, 48 years”

absence[Results]

Race/ethnicity and comorbidities are not reported.

The paper is a clinical trial with human participants, so ethics approval and informed consent are required. However, the abstract and main text do not mention an IRB/ethics committee approval or informed consent. This is a significant omission, though it may be detailed in the full protocol or supplementary materials.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a clinical trial involving human subjects.

Evidence

absence[Entire paper]

No ethics approval statement found.

absence[Entire paper]

No informed consent statement found.

WARNReviewer 2· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Entire paper]

No ethics approval statement is present.

absence[Entire paper]

No informed consent statement is present.

Camrelizumab is identified as an anti-PD-1 antibody, and the chemotherapy regimen is specified with doses (nab-paclitaxel, carboplatin, epirubicin, cyclophosphamide). However, the manufacturer of camrelizumab is not explicitly stated, though the funder is Jiangsu Hengrui Pharmaceuticals. Software tools are not mentioned, but the trial likely used standard statistical software.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (camrelizumab) and chemotherapy agents are identified with doses and regimens, which is adequate for a drug trial.

Evidence

direct quote[Interventions]

“Patients were randomized in a 1:1 ratio to receive either camrelizumab 200 mg (n = 222) or placebo (n = 219) combined with chemotherapy every 2 weeks. The chemotherapy included nab-paclitaxel (100 mg/m 2 ) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m 2 ) and cyclophosphamide (500 mg/m 2 ) every 2 weeks for 8 weeks.”

PASSReviewer 2· 90% conf

The investigational product (camrelizumab) and chemotherapy agents are identified with doses and regimens, which is adequate for a drug trial.

Evidence

direct quote[Introduction]

“Camrelizumab, an anti–PD-1 antibody”

paraphrase[Methods, Interventions]

“The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m2) and cyclophosphamide (500 mg/m2) every 2 weeks for 8 weeks.”

absence[Methods]

Statistical software is not identified.

The primary endpoint (pathological complete response) is reported with rates, 95% CIs, rate difference, and a one-sided p-value. The statistical test is not explicitly named, but it is likely a chi-square or Fisher's exact test. Exact p-values are reported (P = .004). Effect sizes are reported with CIs. Software is not identified, but this is not critical for a clinical trial. Data presentation includes per-group n and CIs.

Sub-criteria

tests namedINADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedN/A

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The primary endpoint analysis is reported with effect sizes, confidence intervals, and a p-value, which is adequate for a clinical trial.

Evidence

direct quote[Results]

“Pathological complete response was achieved in 126 patients (56.8% [95% CI, 50.0%-63.4%]) in the camrelizumab-chemotherapy group and 98 patients (44.7% [95% CI, 38.0%-51.6%]) in the placebo-chemotherapy group (rate difference, 12.2% [95% CI, 3.3%-21.2%]; 1-sided P = .004).”

absence[Methods]

Statistical test not explicitly named.

PASSReviewer 2· 90% conf

The primary analysis is reported with effect sizes and confidence intervals, and the p-value is exact. Statistical tests are not fully named, but the analysis is standard for a clinical trial.

Evidence

direct quote[Results]

“1-sided P = .004”

direct quote[Results]

“rate difference, 12.2% [95% CI, 3.3%-21.2%]”

absence[Methods]

Statistical software is not identified.

The paper mentions a 'Data Sharing Statement: See .' but the actual statement is not included in the provided text. This is vague and does not specify a concrete access route. For a clinical trial, managed access is acceptable, but the mechanism is not described here.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed, and no repository or accession numbers are provided.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See .”

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed, and no repository or accession numbers are provided.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See .”

absence[Entire paper]

No repository deposit is mentioned.

Trial registration is provided (NCT04613674). The primary outcome is reported with results. Limitations are not discussed in the abstract, but may be in the full text. Conclusions are proportional to the evidence. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessINADEQUATE

all outcomes reportedADEQUATE

limitations discussedNOT REPORTED

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, the primary outcome is reported, limitations are not explicitly discussed in the abstract, and funding/COI are disclosed.

Evidence

direct quote[Trial Registration]

“Trial Registration ClinicalTrials.gov Identifier: NCT04613674 (https://clinicaltrials.gov/study/NCT04613674)”

direct quote[Article Information]

“Conflict of Interest Disclosures: None reported. Funding/Support: This study was supported by Jiangsu Hengrui Pharmaceuticals Co, Ltd.”

absence[Abstract]

Limitations are not discussed in the abstract.

PASSReviewer 2· 90% conf

The trial is registered, methods are described in sufficient detail, and conclusions are proportional to the results.

Evidence

direct quote[Abstract, Trial Registration]

“ClinicalTrials.gov Identifier: NCT04613674”

direct quote[Article Information]

“Conflict of Interest Disclosures: None reported. Funding/Support: This study was supported by Jiangsu Hengrui Pharmaceuticals Co, Ltd.”

absence[Discussion]

Limitations are not discussed.

3 copyedit issues flagged: mostly consistency, typo.

Checked 1 reference by DOI: 1 verified.

Reproducibility

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

The published work is generally robust, but an informed reader should weigh the missing explicit ethics approval and informed consent statements, the incomplete data sharing statement, and the lack of a sample size calculation and randomization details. These are reporting gaps that could warrant a correction or clarification from the authors, but they do not invalidate the primary findings.

1.
HIGHethics
Add an explicit ethics approval statement in the Methods section, naming the IRB/ethics committee and protocol number.
A clinical trial involving human subjects must report ethics approval; its absence is a serious reporting gap.
2.
HIGHethics
Add an informed consent statement in the Methods section, describing how consent was obtained.
Informed consent is a fundamental ethical requirement for human research and must be documented.
3.
HIGHdata code
Provide a detailed data availability statement in the manuscript, specifying the access mechanism (e.g., data access committee) and conditions.
The current statement is vague ('See .') and does not allow readers to access the data.
4.
HIGHreporting
Include a sample size calculation in the Methods section, stating the assumed effect size, alpha, and power.
A phase 3 trial should report its power analysis to justify the sample size.
5.
HIGHreporting
Describe the randomization method (e.g., block randomization, stratification) in the Methods section.
Randomization method is essential for assessing allocation concealment and bias.
6.
HIGHreporting
List the inclusion and exclusion criteria in the Methods section.
Clear eligibility criteria are necessary for reproducibility and generalizability.
7.
HIGHstatistics
Name the statistical tests used for the primary and secondary endpoints in the Methods section.
Explicitly naming tests allows readers to verify the analysis.
8.
HIGHstatistics
Identify the statistical software used for analysis in the Methods section.
Software identification is part of standard reporting for reproducibility.
9.
MEDIUMreporting
Add a limitations section in the Discussion, addressing potential biases and generalizability.
Limitations are important for interpreting the results and are expected in clinical trial reports.
10.
MEDIUMreporting
Mention adherence to reporting guidelines (e.g., CONSORT) in the Methods or Acknowledgments.
Reporting guideline adherence improves transparency and completeness.
11.
MEDIUMreporting
Provide more detailed demographics (e.g., race/ethnicity, comorbidities) in the baseline table.
Detailed demographics help assess generalizability and subgroup differences.
12.
MEDIUMethics
Include a statement on regulatory compliance (e.g., Declaration of Helsinki) in the Methods section.
Regulatory compliance is a standard requirement for human research.
13.
LOWcopyedit
Remove duplicate title lines in the manuscript header.
The title is repeated multiple times, which is a formatting error.
14.
LOWstatistics
Consider reporting a two-sided p-value for the primary endpoint for consistency with common practice.
One-sided p-values are less common and may be questioned by readers; two-sided is standard.

Full text (9,260 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.

Read full text (PMC)

Open PDF

DOI

10.1001/jama.2024.23560

Share this Rigor Review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/5cd57c9c-ecde-4250-bc9c-82aa4c80d74f" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/5cd57c9c-ecde-4250-bc9c-82aa4c80d74f/badge" alt="Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 8 high issues for “Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Rigor Record.

Record fingerprint

832397b044847027c8732d19cdf534f7a34f4c8dfec4f7bb89f1430a8bc6c2e8

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →